Thursday, 21 December 2017

Lung Cancer Liquid Biopsy Market - Future Growth & Forecast 2017-2021

MRC Announces the Publication of its Research Report – Global Lung Cancer Liquid Biopsy Market 2017-2021
MRC recognizes the following companies as the key players in the global lung cancer liquid biopsy market: Biocept, Exosome Diagnostics, F. Hoffmann-La Roche, and QIAGEN
Other Prominent Vendors in the market are: AccuraGen, Agena Bioscience, BARD1, BGI, Biodesix, Bio-Rad Laboratories, Cancer Genetics, CellMax Life, Circulogene, CLEARBRIDGE BIOMEDICS, CynvenioBiosystems, EntroGen, Epic Sciences, Epigenomics, Fluxion Biosciences, Freenome, Gencurix, Genetracer Biotech, Genomic Health, Grail, Guardant Health, HeliTec, Inivata, Lonza, MedGenome, Nanoview Diagnostics, Natera, Novogene, OncoCyte, OncoDNA, Pathway Genomics, Personal Genome Diagnostics, Predicine, Shuwen Biotech, Sysmex, Thermo Fisher Scientific, Transgenomic, and Trovagene.
Commenting on the report, an analyst from MRC’s team said: “The latest trend gaining momentum in the market is Vendors' focus on clinical trials. The global lung cancer liquid biopsy market is in its growth stage, which offers a great platform for manufacturers to investigate on products through clinical trials. The increasing funding by big investors such as Amazon, GV, and Johnson and Johnson provides an opportunity for new entrants to penetrate the market with their novel products.”

According to the report, one of the major drivers for this market is Rising incidence of lung cancer. Lung cancer is regarded as one of the highest causes of cancer deaths globally. The two types of lung cancers, which grow and spread differently, are SCLC and NSCLC. The major risk factors for the increased lung cancer are (tobacco) smoking and factors such as asbestosis, air pollution, passive smoking, and abnormalities observed in genes (changes in gene base pairing).

Further, the report states that one of the major factors hindering the growth of this market is High cost of lab testing procedure. The cost of lung cancer liquid biopsy is affordable when compared with the cost of tissue biopsy; however, the cost is still high for emerging countries. For the detection of cancerous cells in the lungs, the liquid biopsy is regarded as an emerging and a more convenient alternative to tissue biopsy, but the cost of the procedure is high, which hinders the adoption rate.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

About Market Reports Center;
Market Reports Center is an e-commerce platform obliging the needs of knowledge workers, experts, professionals who are subject to market research information for their work, or to make strategic business decisions. We are dedicated to create a comprehensive offering of market research which is accurate, credible and affordable.
Market Reports Center currently has more than 4,00,000 plus titles and 50+ Publishers on our platform and growing consistently. We cover more than 35 industry verticals being: Automotive, Electronics, Manufacturing, Pharmaceuticals, Healthcare, Chemicals, Construction, Agriculture, Food, Beverages, Banking & Finance, Media and Government, Public Sector Studies.
Connect for more details:
Sam Collins
Market Reports Center
1-646-883-3044 (US)

Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)